Researchers created a laboratory cell line of BRAF V600E anaplastic thyroid cancer that had become resistant to dabrafenib, a drug that blocks the cancer-driving BRAF protein. Compared with the original cells, the resistant cells had higher levels of PHGDH, an enzyme involved in making serine, and EGFR, a protein that can activate growth signals.

Blocking PHGDH with NCT-503 changed gene networks linked to flexible tumor-cell behavior, stem-like traits and EGFR–MAPK signaling. The inhibitor reduced colony formation, stemness-associated markers and MAPK activity, either alone or with dabrafenib, in the laboratory cell models.